Advertisement

Psychopharmacology

, Volume 231, Issue 6, pp 1063–1078 | Cite as

Using genetic findings in autism for the development of new pharmaceutical compounds

  • Jacob A. S. Vorstman
  • Will Spooren
  • Antonio M. Persico
  • David A. Collier
  • Stefan Aigner
  • Ravi Jagasia
  • Jeffrey C. Glennon
  • Jan K. Buitelaar
Review

Abstract

Rationale

The main reason for the current lack of effective treatments for the core symptoms of autism is our limited understanding of the biological mechanisms underlying this heterogeneous group of disorders. A primary value of genetic research is enhancing our insight into the biology of autism through the study of identified autism risk genes.

Objectives

In the current review we discuss (1) the genes and loci that are associated with autism, (2) how these provide us with essential cues as to what neurobiological mechanisms may be involved, and (3) how these mechanisms may be used as targets for novel treatments. Next, we provide an overview of currently ongoing clinical trials registered at clinicaltrials.gov with a variety of compounds. Finally, we review current approaches used to translate knowledge derived from gene discovery into novel pharmaceutical compounds and discuss their pitfalls and problems.

Conclusions

An increasing number of genetic variants associated with autism have been identified. This will generate new ideas about the biological mechanisms involved in autism, which in turn may provide new leads for the development of novel pharmaceutical compounds. To optimize this pipeline of drug discovery, large-scale international collaborations are needed for gene discovery, functional validation of risk genes, and improvement of clinical outcome measures and clinical trial methodology in autism.

Keywords

Autism Genes Neurobiology Pharmaceutical compounds Biomarker 

Notes

Acknowledgments

The research of EU-AIMS receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115300, the resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), from the EFPIA companies in kind contribution and from Autism Speaks.

Conflicts of interest

WS, SA, and RJ are employed by F. Hoffmann-La Roche. DC is employed by Eli Lilly & Co. JB has been in the past 3 years a consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Novartis, Roche, and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. None of the remaining authors have declared any conflict of interest.

References

  1. Aguero F et al (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7:900–907PubMedCentralPubMedGoogle Scholar
  2. Ameis SH, Szatmari P (2012) Imaging-genetics in autism spectrum disorder: advances, translational impact, and future directions. Front Psychiat 3:46Google Scholar
  3. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, fifth edition. American Psychiatric Publishing, ArlingtonGoogle Scholar
  4. Anagnostou E et al (2012) Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 3:16PubMedCentralPubMedGoogle Scholar
  5. Ashley CT Jr, Wilkinson KD, Reines D, Warren ST (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262:563–566PubMedGoogle Scholar
  6. Bailey A et al (1995) Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25:63–77PubMedGoogle Scholar
  7. Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370–377PubMedGoogle Scholar
  8. Berg JM, Geschwind DH (2012) Autism genetics: searching for specificity and convergence. Genome Biol 13:247PubMedCentralPubMedGoogle Scholar
  9. Berkel S et al (2010) Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 42:489–491PubMedGoogle Scholar
  10. Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 1380:42–77PubMedGoogle Scholar
  11. Bhattacharya A et al (2012) Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in Fragile X syndrome mice. Neuron 76:325–337PubMedCentralPubMedGoogle Scholar
  12. Blankenberg D et al (2010) Galaxy: a web-based genome analysis tool for experimentalists. Chapter 19. Unit 19. Curr Protoc Mol Biol 10:1–21Google Scholar
  13. Boeckers TM (2006) The postsynaptic density. Cell Tissue Res 326:409–422PubMedGoogle Scholar
  14. Bourgeron T (2009) A synaptic trek to autism. Curr Opin Neurobiol 19:231–234PubMedGoogle Scholar
  15. Bozdagi O et al (2010) Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 1:15PubMedCentralPubMedGoogle Scholar
  16. Bruining H et al (2010) Dissecting the clinical heterogeneity of autism spectrum disorders through defined genotypes. PLoS One 5:e10887PubMedCentralPubMedGoogle Scholar
  17. Bucan M et al (2009) Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet 5:e1000536PubMedCentralPubMedGoogle Scholar
  18. Buie T et al (2010) Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 125(Suppl 1):S1–S18PubMedGoogle Scholar
  19. Buitelaar JK (2003) Why have drug treatments been so disappointing? Novartis Found Symp 251:235–244, discussion 245–9, 281–97PubMedGoogle Scholar
  20. Burbidge R, Trotter M, Buxton B, Holden S (2001) Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comput Chem 26:5–14PubMedGoogle Scholar
  21. Butler MG et al (2005) Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42:318–321PubMedGoogle Scholar
  22. Buxbaum JD et al (2002) Association between a GABRB3 polymorphism and autism. Mol Psychiatry 7:311–316PubMedGoogle Scholar
  23. Calfa G, Percy AK, Pozzo-Miller L (2011) Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp Biol Med (Maywood) 236(3–19)Google Scholar
  24. Careaga M, Ashwood P (2012) Autism spectrum disorders: from immunity to behavior. Methods Mol Biol 934:219–240PubMedGoogle Scholar
  25. Cook EH Jr et al (1998) Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet 62:1077–1083PubMedCentralPubMedGoogle Scholar
  26. Correia CT et al (2010) Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav 9:841–848PubMedGoogle Scholar
  27. Curran S et al (2005) An association analysis of microsatellite markers across the Prader-Willi/Angelman critical region on chromosome 15 (q11-13) and autism spectrum disorder. Am J Med Genet B Neuropsychiatr Genet 137B:25–28PubMedGoogle Scholar
  28. de Vrij FM et al (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31:127–132PubMedCentralPubMedGoogle Scholar
  29. Depino AM (2013) Peripheral and central inflammation in autism spectrum disorders. Mol Cell Neurosci 53:69–76PubMedGoogle Scholar
  30. Devlin B, Scherer SW (2012) Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev 22:229–237PubMedGoogle Scholar
  31. Devlin B, Melhem N, Roeder K (2011) Do common variants play a role in risk for autism? Evidence and theoretical musings. Brain Res 1380:78–84PubMedCentralPubMedGoogle Scholar
  32. Dolen G et al (2007) Correction of fragile X syndrome in mice. Neuron 56:955–962PubMedCentralPubMedGoogle Scholar
  33. Dove D et al (2012) Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 130:717–726PubMedGoogle Scholar
  34. Durand CM et al (2012) SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 17:71–84PubMedCentralPubMedGoogle Scholar
  35. Eberhart DE, Malter HE, Feng Y, Warren ST (1996) The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 5:1083–1091PubMedGoogle Scholar
  36. Ecker C, Spooren W, Murphy DG (2013) Translational approaches to the biology of Autism: false dawn or a new era? Mol Psychiatry 18:435–442PubMedCentralPubMedGoogle Scholar
  37. Ehninger D (2013) From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 68:97–105Google Scholar
  38. Ehninger D, Li W, Fox K, Stryker MP, Silva AJ (2008a) Reversing neurodevelopmental disorders in adults. Neuron 60:950–960PubMedCentralPubMedGoogle Scholar
  39. Ehninger D et al (2008b) Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med 14:843–848PubMedCentralPubMedGoogle Scholar
  40. Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat 22:183–198PubMedGoogle Scholar
  41. Fielden MR, Matthews JB, Fertuck KC, Halgren RG, Zacharewski TR (2002) In silico approaches to mechanistic and predictive toxicology: an introduction to bioinformatics for toxicologists. Crit Rev Toxicol 32:67–112PubMedGoogle Scholar
  42. Fox RJ (2010) Methods, systems and software for identifying functional biomolecules. US Patent 7,747,393 B2 (Maxygen, Inc.)Google Scholar
  43. Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125–132PubMedGoogle Scholar
  44. Freitag CM (2007) The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry 12:2–22PubMedGoogle Scholar
  45. Frith U (1991) Autism and Asperger syndrome. Cambridge University Press, CambridgeGoogle Scholar
  46. Furie RA et al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143–1151PubMedCentralPubMedGoogle Scholar
  47. Garbett K et al (2008) Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 30:303–311PubMedCentralPubMedGoogle Scholar
  48. Gauthier J et al (2009) Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B:421–424PubMedGoogle Scholar
  49. Geschwind DH (2009) Advances in autism. Annu Rev Med 60:367–380PubMedCentralPubMedGoogle Scholar
  50. Geschwind DH (2011) Genetics of autism spectrum disorders. Trends Cogn Sci 15:409–416PubMedCentralPubMedGoogle Scholar
  51. Gesundheit B et al (2013) Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 44:1–7PubMedGoogle Scholar
  52. Gipson TT, Johnston MV (2012) Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders. Neural Plast 2012:486402PubMedCentralPubMedGoogle Scholar
  53. Glessner JT et al (2009) Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459:569–573PubMedCentralPubMedGoogle Scholar
  54. Goecks J, Nekrutenko A, Taylor J (2010) Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 11:R86PubMedCentralPubMedGoogle Scholar
  55. Goffin A, Hoefsloot LH, Bosgoed E, Swillen A, Fryns JP (2001) PTEN mutation in a family with Cowden syndrome and autism. Am J Med Genet 105:521–524PubMedGoogle Scholar
  56. Green JJ, Hollander E (2010) Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 7:250–257PubMedGoogle Scholar
  57. Gregory SG et al (2009) Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med 7:62PubMedCentralPubMedGoogle Scholar
  58. Gustafsson C, Govindarajan S, Emig RA, Fox RJ, Roy AK, Minshull JS, Davis C, Cox AR, Patten PA, Castle LA, Siehl DL, Gorton RL, Chen T (2010) Methods, systems and software for identifying functional biomolecules. Maxygen, Inc., Redwood CityGoogle Scholar
  59. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143–1147PubMedGoogle Scholar
  60. Hartshorne TS, Grialou TL, Parker KR (2005) Autistic-like behavior in CHARGE syndrome. Am J Med Genet A 133A:257–261PubMedGoogle Scholar
  61. Hoeffer CA et al (2012) Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav 11:332–341PubMedCentralPubMedGoogle Scholar
  62. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682–690PubMedGoogle Scholar
  63. Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 99:7746–7750PubMedCentralPubMedGoogle Scholar
  64. Jacob S et al (2007) Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci Lett 417:6–9PubMedCentralPubMedGoogle Scholar
  65. Jacquemont S et al (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64Google Scholar
  66. Jamain S et al (2003) Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34:27–29PubMedCentralPubMedGoogle Scholar
  67. Johansson M et al (2006) Autism spectrum disorders and underlying brain pathology in CHARGE association. Dev Med Child Neurol 48:40–50PubMedGoogle Scholar
  68. Kanner L (1968) Autistic disturbances of affective contact. Acta Paedopsychiatr 35:100–136PubMedGoogle Scholar
  69. Kim SA, Kim JH, Park M, Cho IH, Yoo HJ (2006) Association of GABRB3 polymorphisms with autism spectrum disorders in Korean trios. Neuropsychobiology 54:160–165PubMedGoogle Scholar
  70. Kim HG et al (2008) Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 82:199–207PubMedCentralPubMedGoogle Scholar
  71. Kiraly DD, Eipper-Mains JE, Mains RE, Eipper BA (2010) Synaptic plasticity, a symphony in GEF. ACS Chem Neurosci 1:348–365PubMedGoogle Scholar
  72. Klei L et al (2012) Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism 3:9PubMedCentralPubMedGoogle Scholar
  73. Kremer EJ et al (1991) Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 252:1711–1714PubMedGoogle Scholar
  74. Lancaster MA et al (2013) Cerebral organoids model human brain development and microcephaly. Nature 501:373–379Google Scholar
  75. Law AJ et al (2006) Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A 103:6747–6752PubMedCentralPubMedGoogle Scholar
  76. Law AJ, Kleinman JE, Weinberger DR, Weickert CS (2007) Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 16:129–141PubMedGoogle Scholar
  77. Law AJ et al (2012) Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A 109:12165–12170PubMedCentralPubMedGoogle Scholar
  78. Leblond CS et al (2012) Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8:e1002521PubMedCentralPubMedGoogle Scholar
  79. Lemonnier E et al (2012) A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2:e202PubMedCentralPubMedGoogle Scholar
  80. Lerer E et al (2008) Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland adaptive behavior scales and cognition. Mol Psychiatry 13:980–988PubMedGoogle Scholar
  81. Levenga J et al (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42:311–317PubMedGoogle Scholar
  82. Li W et al (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961–1967PubMedGoogle Scholar
  83. Li X, Zou H, Brown WT (2012) Genes associated with autism spectrum disorder. Brain Res Bull 88:543–552PubMedGoogle Scholar
  84. Lipinski C, Hopkins A (2004) Navigating chemical space for biology and medicine. Nature 432:855–861PubMedGoogle Scholar
  85. Liu X et al (2010) Association of the oxytocin receptor (OXTR) gene polymorphisms with autism spectrum disorder (ASD) in the Japanese population. J Hum Genet 55:137–141PubMedGoogle Scholar
  86. Lucht MJ et al (2009) Associations between the oxytocin receptor gene (OXTR) and affect, loneliness and intelligence in normal subjects. Prog Neuropsychopharmacol Biol Psychiat 33:860–866Google Scholar
  87. Luscher C, Huber KM (2010) Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65:445–459PubMedCentralPubMedGoogle Scholar
  88. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307–318PubMedGoogle Scholar
  89. Ma DQ et al (2005) Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet 77:377–388PubMedCentralPubMedGoogle Scholar
  90. Maestrini E et al (1999) Serotonin transporter (5-HTT) and gamma-aminobutyric acid receptor subunit beta3 (GABRB3) gene polymorphisms are not associated with autism in the IMGSA families. The International Molecular Genetic Study of Autism Consortium. Am J Med Genet 88:492–496PubMedGoogle Scholar
  91. Manolio TA et al (2009) Finding the missing heritability of complex diseases. Nature 461:747–753PubMedCentralPubMedGoogle Scholar
  92. Marchetto MC et al (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143:527–539PubMedCentralPubMedGoogle Scholar
  93. Marshall CR et al (2008) Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82:477–488PubMedCentralPubMedGoogle Scholar
  94. Martin ER et al (2000) Analysis of linkage disequilibrium in gamma-aminobutyric acid receptor subunit genes in autistic disorder. Am J Med Genet 96:43–48PubMedGoogle Scholar
  95. Matus A (2000) Actin-based plasticity in dendritic spines. Science 290:754–758PubMedGoogle Scholar
  96. Matus A, Ackermann M, Pehling G, Byers HR, Fujiwara K (1982) High actin concentrations in brain dendritic spines and postsynaptic densities. Proc Natl Acad Sci U S A 79:7590–7594PubMedCentralPubMedGoogle Scholar
  97. McCauley JL et al (2004) A linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit cluster and association to autism. Am J Med Genet B Neuropsychiatr Genet 131B:51–59PubMedGoogle Scholar
  98. McInnes IB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–789PubMedGoogle Scholar
  99. Mei L, Xiong WC (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9:437–452PubMedCentralPubMedGoogle Scholar
  100. Menold MM et al (2001) Association analysis of chromosome 15 gabaa receptor subunit genes in autistic disorder. J Neurogenet 15:245–259PubMedGoogle Scholar
  101. Moessner R et al (2007) Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81:1289–1297PubMedCentralPubMedGoogle Scholar
  102. Moore PA et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260–263PubMedGoogle Scholar
  103. Moy SS et al (2007) Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav Brain Res 176:4–20PubMedCentralPubMedGoogle Scholar
  104. Murphy D, Spooren W (2012) EU-AIMS: a boost to autism research. Nat Rev Drug Discov 11:815–816PubMedGoogle Scholar
  105. Na ES, Nelson ED, Kavalali ET, Monteggia LM (2013) The impact of MeCP2 loss- or gain-of-function on synaptic plasticity. Neuropsychopharmacology 38:212–219PubMedGoogle Scholar
  106. Nakatani J et al (2009) Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 137:1235–1246PubMedCentralPubMedGoogle Scholar
  107. Navarra SV et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731PubMedGoogle Scholar
  108. Nithianantharajah J et al (2013) Synaptic scaffold evolution generated components of vertebrate cognitive complexity. Nat Neurosci 16:16–24PubMedGoogle Scholar
  109. Numis AL et al (2011) Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 76:981–987PubMedGoogle Scholar
  110. O'Roak BJ et al (2012a) Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485:246–250PubMedCentralPubMedGoogle Scholar
  111. O'Roak BJ et al (2012b) Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 338:1619–1622PubMedCentralPubMedGoogle Scholar
  112. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24:805–815PubMedGoogle Scholar
  113. Phelan K, McDermid HE (2012) The 22q13.3 deletion syndrome (Phelan-McDermid Syndrome). Mol Syndromol 2:186–201PubMedCentralPubMedGoogle Scholar
  114. Pinto D et al (2010) Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466:368–372PubMedCentralPubMedGoogle Scholar
  115. Poelmans GFB, Glennon J, Pauls DL, Buitelaar JK (2013) AKAPs integrate genome-wide association findings for autism spectrum disorders into signalling networks regulating steroidogenesis, neurite outgrowth and synaptic function. Translational Psychiatry 3(6):e270Google Scholar
  116. Prather P, de Vries PJ (2004) Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol 19:666–674PubMedGoogle Scholar
  117. Qin M, Kang J, Smith CB (2005) A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience 135:999–1009PubMedGoogle Scholar
  118. Sanders SJ et al (2012) De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485:237–241PubMedCentralPubMedGoogle Scholar
  119. Sanyal A, Lajoie BR, Jain G, Dekker J (2012) The long-range interaction landscape of gene promoters. Nature 489:109–113PubMedCentralPubMedGoogle Scholar
  120. Searls DB (2000) Using bioinformatics in gene and drug discovery. Drug Discov Today 5:135–143PubMedGoogle Scholar
  121. Sharma A et al (2010) Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30:694–702PubMedCentralPubMedGoogle Scholar
  122. Siller SS, Broadie K (2012) Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast 2012:124548PubMedCentralPubMedGoogle Scholar
  123. Silverman JL, Tolu SS, Barkan CL, Crawley JN (2010) Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35:976–989PubMedGoogle Scholar
  124. Silverman JL, Oliver CF, Karras MN, Gastrell PT, Crawley JN (2013) AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 64:268–282PubMedCentralPubMedGoogle Scholar
  125. Soifer HS, Rossi JJ, Saetrom P (2007) MicroRNAs in disease and potential therapeutic applications. Mol Ther 15:2070–2079PubMedGoogle Scholar
  126. Su T et al (2011) Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology (Berl) 215:291–300Google Scholar
  127. Tachibana M et al (2013) Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. J Child Adolesc Psychopharmacol 23:123–127PubMedGoogle Scholar
  128. Takumi T (2010) A humanoid mouse model of autism. Brain Dev 32:753–758PubMedGoogle Scholar
  129. Tansey KE et al (2010) Oxytocin receptor (OXTR) does not play a major role in the aetiology of autism: genetic and molecular studies. Neurosci Lett 474:163–167PubMedGoogle Scholar
  130. Terstappen GC, Reggiani A (2001) In silico research in drug discovery. Trends Pharmacol Sci 22:23–26PubMedGoogle Scholar
  131. Tropea D et al (2009) Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 106:2029–2034PubMedCentralPubMedGoogle Scholar
  132. van Woerden GM et al (2007) Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci 10:280–282PubMedGoogle Scholar
  133. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57:67–81PubMedGoogle Scholar
  134. Verpelli C, Schmeisser MJ, Sala C, Boeckers TM (2012) Scaffold proteins at the postsynaptic density. Adv Exp Med Biol 970:29–61PubMedGoogle Scholar
  135. Vignes M et al (2011) Gene regulatory network reconstruction using Bayesian networks, the Dantzig Selector, the Lasso and their meta-analysis. PLoS One 6:e29165PubMedCentralPubMedGoogle Scholar
  136. Visscher PM, Goddard ME, Derks EM, Wray NR (2012) Evidence-based psychiatric genetics, AKA the false dichotomy between common and rare variant hypotheses. Mol Psychiatry 17:474–485PubMedGoogle Scholar
  137. Vorstman JA, Ophoff RA (2013) Genetic causes of developmental disorders. Curr Opin Neurol 26:128–136PubMedGoogle Scholar
  138. Vorstman JA et al (2006) Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol Psychiatry 11(1):18–28Google Scholar
  139. Vorstman JA et al (2011) A double hit implicates DIAPH3 as an autism risk gene. Mol Psychiatry 16:442–451PubMedCentralPubMedGoogle Scholar
  140. Vorstman JA et al (2013) No evidence that common genetic risk variation is shared between schizophrenia and autism. Am J Med Genet B Neuropsychiatr Genet 162:55–60Google Scholar
  141. Waldman SA, Terzic A (2013) Systems-based discovery advances drug development. Clin Pharmacol Ther 93:285–287PubMedGoogle Scholar
  142. Walsh KS et al (2013) Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 55(2):131–138Google Scholar
  143. Warmuth MK et al (2003) Active learning with support vector machines in the drug discovery process. J Chem Inf Comput Sci 43:667–673PubMedGoogle Scholar
  144. Waterhouse L (2008) Autism overflows: increasing prevalence and proliferating theories. Neuropsychol Rev 18:273–286PubMedGoogle Scholar
  145. Wilson HL et al (2003) Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 40:575–584PubMedGoogle Scholar
  146. Wu S et al (2005) Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry 58:74–77PubMedGoogle Scholar
  147. Yamasue H, Kuwabara H, Kawakubo Y, Kasai K (2009) Oxytocin, sexually dimorphic features of the social brain, and autism. Psychiatry Clin Neurosci 63:129–140PubMedGoogle Scholar
  148. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053–1066PubMedGoogle Scholar
  149. Yang M et al (2012) Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 32:6525–6541PubMedCentralPubMedGoogle Scholar
  150. Yoo HK, Chung S, Hong JP, Kim BN, Cho SC (2009) Microsatellite marker in gamma-aminobutyric acid—a receptor beta 3 subunit gene and autism spectrum disorders in Korean trios. Yonsei Med J 50:304–306PubMedCentralPubMedGoogle Scholar
  151. Yoo HJ, Cho IH, Park M, Yang SY, Kim SA (2012) Family based association of GRIN2A and GRIN2B with Korean autism spectrum disorders. Neurosci Lett 512:89–93PubMedGoogle Scholar
  152. Zhou J, Parada LF (2009) A motor driving PTEN. Nat Cell Biol 11:1177–1179PubMedGoogle Scholar
  153. Zhou J, Parada LF (2012) PTEN signaling in autism spectrum disorders. Curr Opin Neurobiol 22:873–879PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Jacob A. S. Vorstman
    • 1
  • Will Spooren
    • 2
  • Antonio M. Persico
    • 3
    • 4
    • 5
  • David A. Collier
    • 6
  • Stefan Aigner
    • 2
  • Ravi Jagasia
    • 2
  • Jeffrey C. Glennon
    • 7
  • Jan K. Buitelaar
    • 7
  1. 1.Department of Psychiatry, Brain Center Rudolf Magnus, A001.468University Medical Center UtrechtUtrechtThe Netherlands
  2. 2.F. Hoffmann-La Roche, Neuroscience DTABaselSwitzerland
  3. 3.Child and Adolescent NeuroPsychiatry UnitUniversity Campus Bio-MedicoRomeItaly
  4. 4.Department of Experimental NeurosciencesIRCCS Fondazione Santa LuciaRomeItaly
  5. 5.Mafalda Luce Center for Pervasive Developmental DisordersMilanItaly
  6. 6.Discovery Neuroscience ResearchLilly Research Laboratories, Eli Lilly & Co. Ltd, Erl Wood ManorEnglandUK
  7. 7.Department of Cognitive NeuroscienceRadboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and BehaviorNijmegenThe Netherlands

Personalised recommendations